Emergency contraceptives and women’s health remain central in Taiwan’s latest health policy discussions. Officials met Wednesday to review the possible reclassification of emergency oral contraceptives.
The Food and Drug Administration (FDA) explored shifting the morning-after pill from prescription-only to over-the-counter. The move would allow pharmacists to sell the pill directly, without a doctor’s note.
Japan’s trial system served as the meeting’s main reference. In Japan, people over 16 can buy the pill from approved pharmacies. However, buyers must take the pill on site and return to a clinic after three weeks.
FDA official Lin Yi-chu explained Taiwan’s cautious approach. She said emergency contraceptives and women’s health involve many groups. Doctors, pharmacists, parents, and child welfare advocates all raised concerns.
Despite differing opinions, Lin called for cooperation. She said protecting women’s health must remain the top priority.
Taiwan will continue monitoring Japan’s trial. The study will run until March 2026 and include 300 pharmacies and gynecology clinics. Taiwan plans to design its own version based on the findings.
Health officials also intend to submit the trial to an ethics review committee. This step will help ensure local cultural and medical standards are respected.
Tai Yi-yun, a physician at National Taiwan University Hospital, addressed common fears. She said emergency contraceptives do not cause infertility. Ovulation usually returns three months after stopping the pill.
Tai also spoke about other birth control methods. She warned the public that withdrawal often fails due to sperm in pre-ejaculate fluid.
She added that condoms are effective and affordable. Vasectomies, she noted, remain the most reliable way to prevent pregnancy.
Emergency contraceptives and women’s health continue to raise important policy questions. Taiwan’s final decision may set a new standard for reproductive care in the region.
